OncoMatch/Clinical Trials/NCT07502287
Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma
Is NCT07502287 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including EB-DTNB-NK and Fludarabine for relapsed neuroblastoma.
Treatment: EB-DTNB-NK · Fludarabine · Cyclophosphamide — This illustrative Phase 1/Phase 2 study tests allogeneic dual-target GD2/B7-H3 (CD276) CAR-NK cells in children and young adults with relapsed or refractory neuroblastoma. After lymphodepletion, participants receive IV CAR-NK cells;Part A defines the RP2D and Part B estimates preliminary activity
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Neuroblastoma
Biomarker criteria
Required: GD2 expression (positive)
Tumor material available for central assessment of GD2 and B7-H3 expression; at least one target must be positive
Required: CD276 expression (positive)
Tumor material available for central assessment of GD2 and B7-H3 expression; at least one target must be positive
Demographics
Prior therapy
Must have received: standard neuroblastoma therapy
Prior exposure to standard neuroblastoma therapy, including anti-GD2-based therapy, unless contraindicated, unavailable, or declined for a documented medical reason
Cannot have received: genetically modified cellular therapy
Prior genetically modified cellular therapy within the protocol-defined washout window
Lab requirements
Blood counts
adequate hematologic function considered sufficient by protocol-defined laboratory and clinical thresholds
Kidney function
adequate renal function considered sufficient by protocol-defined laboratory and clinical thresholds
Liver function
adequate hepatic function considered sufficient by protocol-defined laboratory and clinical thresholds
Cardiac function
adequate cardiac function considered sufficient by protocol-defined laboratory and clinical thresholds
Adequate organ function: hematologic, renal, hepatic, cardiac, and pulmonary function considered sufficient by protocol-defined laboratory and clinical thresholds
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07502287 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior genetically modified cellular therapy disqualifies patients from enrollment.
Does this trial require GD2?
Yes, GD2 expression is a required biomarker for enrollment.
Does this trial require CD276?
Yes, CD276 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 21 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages